Trump and Netanyahu clash over reports of starvation in Gaza, underscoring tensions between the US and Israel over the humanitarian crisis.
Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making it a top performer in the S&P 500 and Nasdaq 100.
Trump and Netanyahu clash over reports of starvation in Gaza, underscoring tensions between the US and Israel over the humanitarian crisis.
Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making it a top performer in the S&P 500 and Nasdaq 100.